Volume 10,Issue 3
The Advantages of Shenrongbian Pills Combined with PDE5 Inhibitors in the Treatment of Impotence
Objective: To investigate the clinical advantages of Shenrongbian Pills combined with PDE5 inhibitors in the treatment of impotence. Methods: A total of 160 patients with impotence were randomly divided into a combination therapy group and a monotherapy group, with 80 patients in each group. The combination therapy group was treated with Shenrongbian Pills combined with PDE5 inhibitors, while the monotherapy group was treated with PDE5 inhibitors alone. The clinical efficacy, symptom improvement, onset time, and incidence of adverse reactions were compared between the two groups. Results: The total effective rate in the combination therapy group was significantly higher than that in the monotherapy group (P<0.05). The combination therapy group showed superior improvement in impotence symptoms and symptoms related to kidney yang deficiency compared to the monotherapy group (P<0.05). There was no significant difference in the initial onset time between the two groups (P>0.05), but the sustained onset time in the combination therapy group was significantly longer than that in the monotherapy group (P<0.05). The incidence of adverse reactions did not differ significantly between the two groups (P>0.05). Conclusion: The combination of Shenrongbian Pills and PDE5 inhibitors demonstrates significant advantages in the treatment of impotence, as it not only provides rapid onset of action but also offers root-cause conditioning, potent nourishment, and addresses both symptoms and underlying causes, with good safety.
[1] Yan B, Zhang J, Gao Q, 2019, Research progress on the mechanisms of sexual dysfunction caused by chronic prostatitis/chronic pelvic pain syndrome. Chinese Journal of Andrology, 33(2): 69-72.
[2] Wang K, 2023, Research progress on the pathological mechanisms of chronic prostatitis complicated with erectile dysfunction. Chinese Journal of Andrology, 37(3): 110-114.
[3] Zhang S, 2023, Investigation on lifestyle-related risk factors and distribution of TCM syndrome elements in young male patients with erectile dysfunction. Beijing: China Academy of Chinese Medical Sciences.
[4] He H, Yang M, Zhu J, 2023, Clinical application progress of phosphodiesterase type 5 inhibitors. International Journal of Urology and Nephrology, 43(3): 545-548.
[5] Lin Y, 2006, Application of the method of "Xin Gan Hua Yang" in "Treatise on Febrile Diseases". Fujian Journal of Traditional Chinese Medicine, 37(6): 59-60.
[6] Liu B, Hu B, Zhao H, 2025, A brief analysis of the research progress on the treatment of impotence with traditional Chinese medicine from the perspectives of theory, treatment principles, formulas, and herbs. Guangming Journal of Chinese Medicine, 40(2): 407-411.
[7] He F, 2021, Observation on the effect of Shenrongbianwan combined with dapoxetine in the treatment of premature ejaculation. World Latest Medicine Information, 21(101): 253-254.
[8] He F, 2021, Analysis of the effect of Shenrongbianwan combined with PDE5 inhibitors in the treatment of impotence. World Latest Medicine Information, 21(83): 461-462.
[9] Li Y, 2021, Application effect of Shenrongbianwan in kidney deficiency. World Latest Medicine Information, 21(98): 541-542.
[10] Liu Y, Chen B, Gao X, 2021, Research progress on the potential therapeutic effects of type 5 phosphodiesterase inhibitors on chronic complications of diabetes. Modern Practical Medicine, 33(4): 558-560.